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Despite extensive efforts to confirm a direct association between Chlamydia pneumoniae and atherosclerosis,
different laboratories continue to report a large variability in detection rates. In this study, we analyzed
multiple sections from atherosclerotic carotid arteries from 10 endartectomy patients to determine the location
of C. pneumoniae DNA and the number of sections of the plaque required for analysis to obtain a 95%
confidence of detecting the bacterium. A sensitive nested PCR assay detected C. pneumoniae DNA in all patients
at one or more locations within the plaque. On average, 42% (ranging from 5 to 91%) of the sections from any
single patient had C. pneumoniae DNA present. A patchy distribution of C. pneumoniae in the atherosclerotic
lesions was observed, with no area of the carotid having significantly more C. pneumoniae DNA present. If a
single random 30-m-thick section was tested, there was only a 35.6 to 41.6% (95% confidence interval) chance
of detecting C. pneumoniae DNA in a patient with carotid artery disease. A minimum of 15 sections would
therefore be required to obtain a 95% chance of detecting all true positives. The low concentration and patchy
distribution of C. pneumoniae DNA in atherosclerotic plaque appear to be among the reasons for inconsistency
between laboratories in the results reported.
Chlamydia pneumoniae is a gram-negative obligate intra-
cellular bacterium that is responsible for 10% of commun-
ity-acquired pneumonia (3). Infection with C. pneumoniae
appears to be geographically widespread, with seroepidemio-
logical studies showing that 40 to 70% of adults have been
infected at least once in their lifetime (10). In addition to the
bacterium’s role in respiratory disease, there is growing evi-
dence that C. pneumoniae may be involved in the pathogenesis
of atherosclerosis. Seroepidemiological studies first implicated
C. pneumoniae as an independent risk factor for cardiovascular
diseases (12). Since then, C. pneumoniae has been detected in
human atherosclerotic lesions by various techniques, including
cell culture (4), electron microscopy (7), immunohistochemis-
try, and PCR (4, 5). While detection rates vary considerably,
C. pneumoniae has been detected, on average, in 59% of ath-
eromatous arteries and rarely in nondiseased arteries (15).
Despite extensive efforts to confirm a direct association be-
tween the bacterium and atherosclerosis, different laboratories
continue to report a large variability (from 0 to 100%) in
detection rates (5, 9). These large variations may be attributed
to either (i) differences in detection methodology or (ii) the
irregular distribution of C. pneumoniae in the plaque, influenc-
ing sample selection and hence positivity rates. The aim of this
study was to determine the location and number of sections of
the plaque that are required for analysis to obtain a 95%
confidence interval (CI) for detecting the bacterium in patients
with carotid artery disease (CAD).
MATERIALS AND METHODS
Patients and serology. This study was conducted with the approval of the
Queensland University of Technology Human Ethics Committee (1736H). The
study analyzed a subset of 10 patients from a larger cohort of 54 CAD patients
who were undergoing elective surgery (carotid endartectomy). All patients gave
their informed consent prior to surgery. Atherosclerotic plaques removed at the
time of surgery were immediately fixed in 10% formaldehyde for subsequent
PCR analysis. The presence of serum antibodies to Chlamydia was determined by
the MRL Diagnostics (Cypress, Calif.) immunoglobulin G (IgG) microimmuno-
fluorescence (MIF) test and the Medac Diagnostika (Wedel, Germany) IgG-IgA
recombinant enzyme-linked immunosorbent assay (ELISA). The serum samples
were considered positive when there were titers of 32 for the MIF assay and
100 for the Medac assay.
Preparation of carotid arteries for PCR. Each carotid artery was cut trans-
versely into smaller sections of 5 mm, and their positions in relation to the
carotid bifurcation were recorded. Each portion of formalin-fixed plaque spec-
imen was decalcified, embedded in paraffin, and processed according to conven-
tional techniques. A series of 5-m-thick sections were cut. Six sequential sec-
tions (total sample, 30 m) were pooled and assayed by a C. pneumoniae-specific
nested PCR. At least five serial sets of 30 m for PCR followed by 15 m for
histopathology were cut from four highly stenotic areas adjacent to the carotid
bifurcation. For each patient, therefore, this involved the testing of a minimum
total of 20 sets of 30 m of plaque by PCR.
DNA was extracted from each pooled 30-m section of paraffin-embedded
carotid tissue from each patient using the QIAamp tissue kit (Qiagen, Mel-
bourne, Australia). The 60 l of DNA extract was stored at 70°C until it was
tested.
ompA PCR. C. pneumoniae DNA was detected using a nested PCR assay
targeting a 366-bp fragment of the C. pneumoniae ompA gene (1). The nested
PCR used was highly specific and could detect as few as 10 chlamydial bodies.
For both rounds, DNA (minimum concentration, 10 ng per PCR) was amplified
in 25-l volumes containing 1 M primers, 200 M deoxyribonucleotides, 1
PCR buffer, 1.2 U of Taq polymerase, and 1 l of the DNA sample or first-round
template. Each sample was tested in conjunction with controls: negative controls
with no template added and positive controls containing 100 copies of C. pneu-
moniae 446-bp first-round PCR product. Negative controls were included after
every third test sample to ensure that there was no aerosol contamination. Ten
percent of the test samples were spiked with 100 copies of C. pneumoniae 446-bp
first-round PCR product to test for PCR inhibition. Each sample was tested in
duplicate. At least one of the two duplicates needed to be PCR positive for the
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specimen to be recorded as C. pneumoniae positive. All duplicates were random-
ized and tested on different days, and the results were scored in a blinded
manner. DNA sequencing was performed on selected PCR products to confirm
that C. pneumoniae DNA was indeed being amplified. Sequencing of the PCR
product was done using the standard dideoxy sequencing method of Sanger et al.
(13). All samples were confirmed as C. pneumoniae using a BLAST search (http:
//www.ncbi.nlm.nih.gov/BLAST), and ecrustalw in WebANGIS was used to align
the existing C. pneumoniae sequences to the test samples. All sequences were
99.7% homologous with previously documented strains of C. pneumoniae.
Statistical analysis. Resampling techniques were employed to determine the
likelihood of successfully detecting C. pneumoniae in 1 to 20 sections from a
CAD patient. In order to avoid making distributional assumptions from the
resampling results, the 95% CIs were generated from the percentiles 2.5 and
97.5%.
RESULTS
All patients displayed at least two of the established risk
factors for cardiovascular disease (age, sex, hyperlipidemia,
hypertension, hyperhomocysteinemia, ischemic heart disease,
diabetes, family history of premature cardiovascular disease,
and smoking status). Serum specimens from the nine patients
(excluding patient 8) were examined by MIF tests and ELISA
for the presence of antibodies to C. pneumoniae. Antibody
titers from three of the nine patients (patients 5, 6, and 7)
indicated a preexisting infection with Chlamydia by the MIF
test. The ELISA indicated that two of the nine patients (pa-
tients 3 and 7) had acute C. pneumoniae infections. The MIF
and ELISA results did not correlate for three of the seropos-
itive patients.
C. pneumoniae was detected in all 10 of the atherosclerotic
carotids (Table 1). However, the percentage of sections that
were PCR positive and the reliability of the duplicates varied
considerably, both between patients and also at different sites
within the plaque. On average, 42% (ranging from 5 to 91%)
of the sections from any single patient had C. pneumoniae
DNA present. PCR inhibition was not a significant problem,
since when 10% of the samples were spiked with 100 molecules
of C. pneumoniae DNA, no PCR inhibition was observed. Of
20 PCR products that were extracted from the gels and
sequenced, all were confirmed as true C. pneumoniae products.
Two criteria were used to determine if a section of plaque
was C. pneumoniae positive: (i) either duplicate test should be
positive (single positive) or (b) both duplicate tests must be
positive (double positive). All patients were PCR positive for
C. pneumoniae using the single-positive criterion, while only 8
of the 10 patients displayed double positives (Table 1). The
number of positive sections and the patchy distribution of C.
pneumoniae DNA were consistent in different regions of the
diseased arteries (internal carotid and common carotid).
Resampling techniques were used to determine the chance
of detecting C. pneumoniae by PCR in 1 to 20 sections from the
FIG. 1. Success rate for detecting C. pneumoniae by PCR in 1 to 20
sections from atherosclerotic carotid artery plaques. Each section was
tested in duplicate. The error bars indicate the 95% CI.
TABLE 1. Distribution of C. pneumoniae DNA within atherosclerotic carotid arteries from 10 endartectomy patientsa
Patient
No. of PCR-positive sections
Single positive Double positive
Internal
carotid Bifurcation
Common
carotid Total % PCR
positive
Internal
carotid Bifurcation
Common
carotid Total % PCR
positive
i ii i ii
1 5/5 16/7 7/7 4/5 91 5/5 10/17 2/7 2/5 54
2 5/5 3/5 0/5 3/5 55 5/5 3/5 0/5 3/5 55
3 2/6 1/5 13/22 5/12 47 0/6 0/5 6/22 1/12 16
4 3/5 5/5 1/5 0/5 45 1/5 4/5 1/5 0/5 30
5 2/5 1/5 1/5 5/5 45 1/5 1/5 0/5 2/5 20
6 3/5 0/5 1/5 2/5 30 0/5 0/5 0/5 0/5 0
7 0/5 1/5 1/5 4/5 30 0/5 0/5 0/5 4/5 20
8 0/5 1/5 5/5 0/5 30 0/5 1/5 3/5 0/5 20
9 0/5 0/5 0/5 1/5 5 0/5 0/5 0/5 1/5 5
10 0/5 1/5 0/6 0/5 5 0/5 0/5 0/6 0/5 0
Average % positive 39 35 34 42 24 24 14 25
a Thirty-micrometer-thick sections from four 5-mm segments (internal carotid, bifurcation, and two adjacent segments [i and ii] of the common carotid) were analyzed
per patient. Each section was tested in duplicate for C. pneumoniae. Single positive, detected in at least one of the duplicates; double positive, detected in both
duplicates. The fractions represent the number of PCR-positive sections out of the total number of sections tested.
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sample population (Fig. 1). The results showed that when a
single random 30-m-thick section was tested, there was only
a 35.6 to 41.6% (95% CI) chance of detecting C. pneumoniae
DNA in a patient. A minimum of 15 sections was required to
obtain a 95% chance of detecting all true positives using the
single-PCR-positive criterion. When only the test results that
were repeatedly positive by PCR were included, the chance of
detecting C. pneumoniae in one section was 22%.
DISCUSSION
When extensive sampling of the 10 patients was performed
(a total of 20 30-m-thick sections analyzed per patient), all
10 were found to have C. pneumoniae DNA present at one or
more locations within the plaque. By comparison, if the
present commonly used approach of testing a single section
was used, then there was only a 35.6 to 41.6% (95% CI) chance
of detecting C. pneumoniae DNA. The small amounts and
patchy distribution of C. pneumoniae DNA in atherosclerotic
plaque are among the reasons for the inconsistency between
laboratories in results reported.
Based on the present patient group, 15 sections would need
to be tested to have a 95% confidence level for recording true
C. pneumoniae positives. Previous studies examining the pres-
ence of C. pneumoniae in human atherosclerotic arteries have
usually tested a single 4- to 8-m-thick section, while some
have attempted to test the whole lesion (5, 16). When large
amounts of plaque are tested, PCR inhibitory factors become
problematic. By comparison, while inhibitors may be less of a
problem with a single section, this approach will result in a
gross underestimation of the true prevalence of the microor-
ganism in patients with cardiovascular disease.
There was no obvious correlation between the presence of
C. pneumoniae DNA and (i) the presence of C. pneumoniae
antibodies in each patient or (ii) traditional cardiovascular
disease risk factors. The lack of a direct relationship between
C. pneumoniae DNA and antibodies was not unexpected, as
this finding has been reported previously (2). Thus, serological
tests do not appear suitable for predicting a vascular C. pneu-
moniae infection.
Nested PCR assay is considered a sensitive means of detect-
ing C. pneumoniae DNA in atherosclerotic tissues, yet it is
often problematic due to an increased risk of contamination.
Processing of clinical specimens, preparation of the PCR mix-
ture, and addition of template were all conducted in separate
areas to avoid cross-contamination. The use of negative con-
trols every third sample was included to ensure that no false
positives were obtained.
Our findings have shown that replicate testing of each sam-
ple increased the proportion of PCR-positive specimens. We
consider the results for patients for whom only one of the two
duplicates was positive to be true positives and not due to
contamination, as all negative controls were as expected. Pre-
vious publications have also reported inconsistencies with re-
peated PCR testing of samples (8, 11, 14, 17). Mahony et al.
compared five different PCR assays and found that the sensi-
tivity for detecting C. pneumoniae DNA from culture material
was 0.005 inclusion-forming units/test, while the reproducibil-
ity decreased notably below 0.01 inclusion-forming units (8).
Smieja et al. observed that repeat testing of the same sam-
ple increased the proportion of positive clinical specimens
(14). This poor reproducibility may be attributed to the small
amount of C. pneumoniae DNA present in the diseased artery,
to sampling errors arising from the use of such small sample
volumes, to the observation that chlamydiae tend to cluster,
and to PCR inhibition. Thus, without extensive testing of the
sample, any result will be an underestimation of the true prev-
alence of C. pneumoniae.
The quantity (on average, 42% of sections; 102 of 241 sec-
tions from 10 patients) and irregular distribution of C. pneu-
moniae DNA in the plaque were consistent findings that we
observed throughout the diseased carotid artery. Only one
other study has analyzed multiple sections from the same tissue
specimen. Kuo and Campbell analyzed 167 sections from 51
positive patients and found 68% of the sections positive for C.
pneumoniae by immunocytochemistry (6). A possible explana-
tion for the slightly higher detection rate compared to our
study may be due to methodological differences or to sampling
various arterial tissues (aorta, carotid, and coronary arteries)
rather than one arterial site (carotid). The aorta, coronary, and
iliac arteries appear to have two to four times more C. pneu-
moniae DNA present than the carotid artery (16). Our study is
the first to comprehensively examine the presence of C. pneu-
moniae throughout more than three sections of the carotid
artery by PCR. Due to the low concentration and patchy dis-
tribution of C. pneumoniae DNA in atherosclerotic plaques,
sampling procedures should analyze more sections from one
arterial site to gain greater confidence in recording true posi-
tives. An improved understanding of the distribution of C.
pneumoniae in atherosclerotic plaque provides important new
information about the potential role of this organism in athero-
genesis.
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